SMN2 and proximal spinal muscular atrophy: In December 2016, Nusinersen (SPINRAZATM), an antisense oligonucleotide that modulates SMN2 splicing, received approval as a therapy for all SMA types, becoming the first commercially available drug for this disease 14.